Table 1. Patients’ Characteristics (n = 67).

From: Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide

Variable
Median age, years (range) 73 (47-89)
Biopsy Gleason score, n (%)
<8 16 (23.8%)
≥8 50 (73.6%)
NA 1 (1.4%)
Median PSA at pretreatment, ng/mL (range) 14.2 (0.224-8214)
Clinical stage at diagnosis, n (%)
N0M0 31 (46.2%)
N1M0 4 (5.9%)
M1 32 (47.7%)
Prior docetaxel 23 (34.3%)
Prior abiraterone 8 (11.9%)
Corticosteroid administration 18 (26.8%)
Median psoas muscle ratio, cm3/m (range) 160.1 (87.3-240.1)
Median visceral fat, % (range) 36.4 (11.1-58.3)
Median body fat, % (range) 34.5 (12.3-51.5)
Median V/S ratio, ratio (range) 1.04 (0.46-2.12)
Fatigue (gradea,b)
0 36 (53.7%)
1 19 (28.3%)
2 10 (14.9%)
3 2 (2.9%)
Anorexia (grade)
0 44 (65.6%)
1 13 (19.4%)
2 7 (10.4%)
3 3 (4.4%)
4 0
5 0
Pain (grade)
0 54 (80.5%)
1 6 (8.9%)
2 2 (2.9%)
3 5 (7.4%)
Insomnia (grade)
0 63 (94.0%)
1 3 (4.4%)
2 1 (1.4%)
3 0
Table 2. Univariate Analysis of Adverse Effects in CRPC Patients Treated with Enzalutamide. Psoas Muscle Ratio, Body Fat, and Visceral Fat Volumes, and the V/S Ratio Were Used to Divide the Patients into Two Groups Following the Median Values for Each Parameter.

From: Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide

Parameter Fatigue (>G2) Anorexia (>G2) Pain (>G2) Insomnia (>G1)
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age 1.012 0.939-1.091 0.744 1.075 0.984-1.176 0.108 0.942 0.858-1.033 0.208 1.018 0.901-1.151 0.765
Prior docetaxel
1 1 1 1
+ 0.947 0.252-3.555 0.936 0.792 0.184-3.406 0.755 2.877 0.585-14.147 0.193 0.621 0.060-6.331 0.678
Corticosteroid
1 1 1 1
+ 0.487 0.095-2.477 0.386 2.047 0.504-8.316 0.316 2.25 0.451-11.222 0.326 0.901 0.087-9.275 0.93
Psoas muscle ratio
 <160.1 1 1 1 1
 ≥160.1 3.875 1.016-17.134 0.047 0.093 0.011-0.784 0.029 0.801 0.165-3.893 0.784 1.099 0.145-8.303 0.924
Body fat
 <34.5 1 1 1 1
 ≥34.5 2.074 0.558-7.698 0.275 0.559 0.142-2.196 0.405 1.247 0.256-6.057 0.784 2.906 0.286-29.468 0.366
Visceral fat
 <36.4 1 1 1 1
 ≥36.4 2.230 0.600-8.282 0.230 0.600 0.152-2.356 0.464 0.701 0.144-3.407 0.660 3.096 0.305-31.399 0.338
V/S ratio
 <1.04 1 1 1 1
 ≥1.04 1.350 00381-4.776 0.641 4.444 0.866-22.783 0.073 0.327 0.058-1.821 0.202 2.906 0.286-29.468 0.366
Table 3. Relationship between Psoas Muscle Ratio and Each Parameter.

From: Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide

Psoas muscle ratio
Parameter <160.1 ≥160.1 P value
Median age (range) 72 (47-87) 68 (55-89) 0.028
Prior docetaxel 13 (19.4) 10 (14.9) 0.611
Prior abiraterone 6 (8.9) 2 (2.9) 0.169
Corticosteroid administration 10 (14.9) 8 (11.9) 0.741
Median body fat (range) 31.7 (12.3-49.8) 37.1 (22.2-51.5) 0.002
Median visceral fat (range) 31.8 (11.1-58.3) 39.9 (18.3-55.8) 0.001
Median V/S ratio (range) 0.96 (0.46-1.97) 1.15 (0.58-2.12) 0.118
PAGE TOP